1. Home
  2. MDLZ vs REGN Comparison

MDLZ vs REGN Comparison

Compare MDLZ & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mondelez International Inc.

MDLZ

Mondelez International Inc.

HOLD

Current Price

$54.34

Market Cap

78.9B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$755.77

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDLZ
REGN
Founded
2000
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.9B
73.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
MDLZ
REGN
Price
$54.34
$755.77
Analyst Decision
Buy
Buy
Analyst Count
18
23
Target Price
$68.39
$795.74
AVG Volume (30 Days)
10.0M
1.1M
Earning Date
02-03-2026
02-03-2026
Dividend Yield
3.70%
0.47%
EPS Growth
N/A
2.88
EPS
2.69
41.59
Revenue
$37,645,000,000.00
$14,247,800,000.00
Revenue This Year
$7.35
$1.95
Revenue Next Year
$4.04
$5.47
P/E Ratio
$20.07
$17.82
Revenue Growth
4.13
2.89
52 Week Low
$53.13
$476.49
52 Week High
$71.15
$790.98

Technical Indicators

Market Signals
Indicator
MDLZ
REGN
Relative Strength Index (RSI) 36.21 61.81
Support Level $53.13 $689.88
Resistance Level $56.33 $753.61
Average True Range (ATR) 1.02 20.54
MACD -0.06 -4.09
Stochastic Oscillator 26.96 65.15

Price Performance

Historical Comparison
MDLZ
REGN

About MDLZ Mondelez International Inc.

Mondelez has operated independently since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales as of the end of fiscal 2024), chocolate (31%), gum/candy (11%), beverage (3%), and cheese and grocery (6%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury. The firm derives around one-third of its revenue from developing markets, just more than one-third from Europe, and the remainder from North America.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: